欢迎来到范德生物BIOFOUNT
范德生物中国

中文范德生物中文语言

范德生物产品购买购物车
0
搜索
Sergliflozin etabonate_408504-26-7_产品详情
408504-26-7
  • Sergliflozin etabonate

  • names:

    ethyl (((2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(2-(4-methoxybenzyl)phenoxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate

  • CAS号:

    408504-26-7

    MDL Number:
  • MF(分子式): C23H28O9 MW(分子量): 448.46
  • EINECS: Reaxys Number:
  • Pubchem ID: Brand:BIOFOUNT
Sergliflozin etabonate
货品编码 规格 纯度 价格 (¥) 现价(¥) 特价(¥) 库存描述 数量 总计 (¥)
快速询价
收起
你想询价的产品
请准确填写您的联系方式,以便为您提供最好的服务。
中文别名 ethyl (((2R,3S,4S,5R,6S)-3,4,5-trihydroxy-6-(2-(4-methoxybenzyl)phenoxy)tetrahydro-2H-pyran-2-yl)methyl) carbonate
英文别名 GW-869682; GW-869682X; KGT-1251; GW869682; GW869682X; KGT1251; GW 869682; GW 869682X; KGT 1251; Sergliflozin etabonate
CAS号 408504-26-7
Inchi InChI=1S/C23H28O9/c1-3-29-23(27)30-13-18-19(24)20(25)21(26)22(32-18)31-17-7-5-4-6-15(17)12-14-8-10-16(28-2)11-9-14/h4-11,18-22,24-26H,3,12-13H2,1-2H3/t18-,19-,20+,21-,22-/m1/s1
InchiKey QLXKHBNJTPICNF-QMCAAQAGSA-N
分子式 Formula C23H28O9
分子量 Molecular Weight 448.46
溶解度Solubility
性状 Solid powder
储藏条件 Storage conditions Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).
产品说明 Sergliflozin etabonate(CAS:408504-26-7):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。
IntroductionSergliflozin etabonate is a SGLT-2 inhibitor potentially for the treatment of type 2 diabetes and obesity
Application1
Application2
Application3
警示图
危险性 Warning
危险性警示
安全声明
安全防护
备注
[1]Hussey EK, Dobbins RL, Stoltz RR, Stockman NL, O'Connor-Semmes RL, Kapur A, Murray SC, Layko D, Nunez DJ. Multiple-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy overweight and obese subjects: a randomized double-blind study. J Clin Pharmacol. 2010 Jun;50(6):636-46. doi: 10.1177/0091270009352185. PubMed PMID: 20200268.
[2]Katsuno K, Fujimori Y, Ishikawa-Takemura Y, Isaji M. Long-term treatment with sergliflozin etabonate improves disturbed glucose metabolism in KK-A(y) mice. Eur J Pharmacol. 2009 Sep 15;618(1-3):98-104. doi: 10.1016/j.ejphar.2009.07.001. PubMed PMID: 19615995.
[3] Fujimori Y, Katsuno K, Ojima K, Nakashima I, Nakano S, Ishikawa-Takemura Y, Kusama H, Isaji M. Sergliflozin etabonate, a selective SGLT2 inhibitor, improves glycemic control in streptozotocin-induced diabetic rats and Zucker fatty rats. Eur J Pharmacol. 2009 May 1;609(1-3):148-54. doi: 10.1016/j.ejphar.2009.03.007. PubMed PMID: 19281809.
[4] Hussey EK, Clark RV, Amin DM, Kipnes MS, O'Connor-Semmes RL, O'Driscoll EC, Leong J, Murray SC, Dobbins RL, Layko D, Nunez DJ. Single-dose pharmacokinetics and pharmacodynamics of sergliflozin etabonate, a novel inhibitor of glucose reabsorption, in healthy volunteers and patients with type 2 diabetes mellitus. J Clin Pharmacol. 2010 Jun;50(6):623-35. doi: 10.1177/0091270009351879. PubMed PMID: 20056803.
    对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
        新闻
        抱歉,暂无数据!
        My title page contents